PT  - JOURNAL ARTICLE
AU  - Re, Daniel
AU  - Seitz-Polski, Barbara
AU  - Carles, Michel
AU  - Brglez, Vesna
AU  - Graça, Daisy
AU  - Benzaken, Sylvia
AU  - Liguori, Stéphane
AU  - Zahreddine, Khaled
AU  - Delforge, Margaux
AU  - Verrière, Benjamin
AU  - Chamorey, Emmanuel
AU  - Jérôme, Barrière
TI  - Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignancies
AID  - 10.1101/2021.07.18.21260669
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.18.21260669
4099  - http://medrxiv.org/content/early/2021/07/22/2021.07.18.21260669.short
4100  - http://medrxiv.org/content/early/2021/07/22/2021.07.18.21260669.full
AB  - BACKGROUND Immunocompromised patients such as patients with hematological malignancies have impaired immune response to two doses of BNT162b2 (Pfizer / BioNtech) vaccine against SARS-CoV-2. Evaluation of a repeated immune stimulation with a third vaccine dose is needed.METHODS a vaccine monitoring observatory was conducted in outpatients who were treated for lymphoid malignancies (LM) to monitor both immune and cellular response measured the day of administration of the dose 3 of the mRNA vaccine BNT162b2 and again three to four weeks. Elecsys ® Anti-SARS-CoV-2 immunoassay was used to asses to the level of SARS-CoV-2 anti-Spike (S) antibodies (Abs) titer and SARS-CoV-2-specific T-cell responses were assessed by a whole blood Interferon-Gamma Release Immuno Assay (IGRA) (QuantiFERON Human IFN-gamma SARS-CoV-2, Qiagen®).RESULTS Among the 43 assessable patients (suffering from chronic lymphocytic leukemia (CLL) (n=15), indolent and aggressive B cell non-Hodgkin lymphoma (NHL) (n=14), and multiple myeloma (MM) (n=16)), 18 (41,8%) had no anti-S Abs before the dose 3 of BNT162b2 vaccine (n=9 CLL, n=8 NHL, n=1 MM), and they all 18 remained negative after the dose 3. Amongst the 25 patients with positive anti-S titers before dose 3, all patients remained positive and 23 patients increased their anti-S titer after dose 3. Patients with CLL and/or with previous anti-CD20 therapy treated within 12 months of administration of dose 3 had no significant increase of the humoral response. Among 22 available patients, dose 3 of BNT162b2 vaccine significantly increased the median IFN-gamma secretion. On eight (36.4%) patients who were double-negative for both immune and cellular response, five (22.7%) patients remained double-negative after dose 3.CONCLUSIONS Dose 3 of BNT162b2 vaccine stimulated humoral immune response among patients with LM, in particular patients with MM (who had higher anti-S baseline titer after dose 2) and those with no anti-CD20 treatment history within a year. T-cell response was increased among patients in particular with no active chemotherapy regimen. Our data support the use of an early third vaccine dose among immunocompromised patients followed for LM though some of them will still have vaccine failure.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialAll participants signed a written informed consent and accepted their participation in this registered trial in accordance with ethical and legal French policies (Registration number F20210324145532)Funding StatementThis research was supported by a grant from Conseil Departemental des Alpes-Maritimes and from the Agence Nationale pour la Recherche AO-Flash-COVID.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The third dose was made according to the French National Authority for health (ref 10) published on April 11th 2021 recommending the use of a third dose in immunosuppressed patients. The current study has been discussed with the president of the local ethics committee of the Antibes hospital where all patients were followed and vaccinated (Dr Philippe de Swardt philippe.deswardt@ch-antibes.fr). Dr de Swardt decided that the current observatory was conducted according to the French policies and therefore that a formal local or national CPP (Comite de protection des personnes) statement was not necessary according to French policies. However, all participants signed a written informed consent and accepted their participation in this registered observatory in accordance with ethical and legal French policies (Registration number F20210324145532). All data were prospectively collected on an electronic anonymous data set. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data are available